Q-omics provides the consensus-scored OS9 profile across patient tissues and cancer cell-line models. OS9 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, OS9 is differentially expressed in 13, with the highest sampling consensus in KIRC. Additionally, OS9 RNA expression shows 19,270 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight MESO, KIRC, and ACC as cancer lineages where OS9 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for OS9 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes OS9 survival associations across molecular data types. OS9 RNA expression shows survival associations in the most cancer types (27), followed by mutation status (3) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible OS9 RNA expression–survival associations across cancer types. High OS9 expression shows unfavorable associations in MESO, HNSC, LGG, ACC, BLCA and KICH. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify MESO as the clearest survival context for OS9 RNA expression.
This table summarizes OS9 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 7. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for OS9. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. OS9 shows lower tumor expression in THCA and COAD and higher tumor expression in KIRC, HNSC, LIHC and STAD. The KIRC box plot shows higher OS9 RNA expression in tumor versus normal tissue (log2 FC = +0.629, t-test p < 0.001).
This table shows molecular features associated with OS9 in patient tissues and cancer cell lines. In patient samples, OS9 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, OS9 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD and UPPER_AERODIGESTIVE_TRACT.
